HDAX Therapeutics Analysis: $5M Raised
What is HDAX Therapeutics?
Proprietary 2-site HDAC6 binding technology for neurology and cardiovascular diseases
Location
Mississauga, Canada
Employees
11-50
Founded
2021
Other Considerations
None available
Product Features & Capabilities
- 2-site HDAC6 binding small molecules
- Targeted therapy for neuropathies and cardiovascular diseases
- Enhanced drug selectivity and safety profile
Use Cases
Develop small molecules to treat HDAC6-related neuropathies; Design therapies for cardiovascular diseases with poor treatment standards; Improve targeting of HDAC6 to enhance drug efficacy; Advance differentiated small molecules for neurology indications; Create safer, more selective treatments for cytoskeleton-related disorders
See something that needs updating? Suggest edits to this profile.